Lantheus, NanoMab to offer novel biomarker to develop immuno-oncology therapies

This article was originally published here

As part of strategic collaboration and licence agreement, the partnership will offer first broadly-available imaging biomarker research tool to pharmaceutical companies and major academic centers carrying out research

The post Lantheus, NanoMab to offer novel biomarker to develop immuno-oncology therapies appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply